期刊文献+

磁靶向定位灌注化疗膀胱癌磁性吡柔比星纳米粒的制备与评价 被引量:2

Synthesis of magnetic pirarubicin nanoparticles for targeted intravesical chemotherapy to treat bladder cancer
下载PDF
导出
摘要 目的构建一种新型的磁靶向定位灌注化疗膀胱癌的吡柔比星纳米制剂,并探讨其磁靶向定位及抗膀胱癌细胞特性,为定位灌注化疗膀胱癌的临床应用提供帮助。方法通过N-N'-羰基二咪唑(CDI)交联剂将治疗膀胱癌的临床药物吡柔比星(pirarubicin,THP)连接在表面氨基化的四氧化三铁(Fe3O4)磁性纳米粒上,制备具有磁性的THP纳米制剂,并在体外考察其磁定位性能和对膀胱癌细胞的抑制作用。结果 THP成功地连接到了粒径40 nm左右的Fe3O4磁性纳米粒上,磁性药物制剂在不同p H值的缓冲液中药物在90%以上,并可在外界磁场作用下定位于靶向部位。对膀胱癌细胞可造成THP和Fe3O4双重抑制效果,抑制率高达58.44%。结论该纳米制剂可通过外界磁场定位于靶向部位,膀胱癌细胞抑制效果明显,为临床定位灌注化疗的应用奠定了基础。 Objective We synthesized novel magnetic pirarubicin nanoparticles for targeted intravesical chemotherapy to treat bladder cancer .Methods Pirarubicin was grafted on Fe 3 O4 nanoparticles which were surface-functionalized with amino-groups via N, N′-Carbonyldiimidazoleas targeted intravesical infusion chemotherapy agents.Mimetic position in vitro by external magnetic field and inhibition to bladder cancer cells of prepared agents were demonstrated.Results Pirarubicin was successfully grafted on magnetic Fe3 O4 nanoparticles whose size were around 40 nm.The residual of pirarubicin on the pharmaceutic agents was above 90% in buffer solutions of various pH.They also could be positioned to certain area by external magnetic. Meanwhile, the prepared magnetic pirarubicin nanoparticles gave multiple-inhibition to bladder cancer cells by THP and Fe3 O4.The inhibition rate was up to 58.44% after co-cultured for 2 h.Conclusions These magnetic pirarubicin nanoparticles have a great potential for clinical use in infusion chemotherapy.
出处 《北京生物医学工程》 2015年第3期267-272,共6页 Beijing Biomedical Engineering
基金 重庆市万州区科委科技计划项目(201303005) 重庆大学大学生科研训练计划项目资助
关键词 膀胱癌 吡柔比星 FE3O4 灌注化疗 磁靶向 bladder cancer pirarubicin infusion chemotherapy magnetic targeting
  • 相关文献

参考文献22

  • 1Ahmedin J, Freddie B, Melissa M, et al. Global cancer statistics [J]. Ca CancerJClin, 2011, 61(2) :69-90.
  • 2Sten H, Hans H, Claes A, et al. The relationship among multiple recurrences, progression and prognosis of patients with stafes Ta and T1 transitional cell cancer of the bladder followed for at least 20 years [J].J Urology, 1995, 153 (6):1823- 1827.
  • 3Georgios G, Jason E, Seth P, et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-lnvasive urothelial carcinoma of the bladder [J]. Eur Urol, 2013, 63(1) :45-57.
  • 4赫志强.经尿道切除膀胱肿瘤治疗膀胱癌的疗效和安全性分析[J].中国医药科学,2013,3(13):25-27. 被引量:7
  • 5陈智林,李健.同期经尿道电切术治疗浅表性膀胱癌合并前列腺增生的临床效果观察[J].中国医药科学,2014,4(2):178-180. 被引量:16
  • 6Arnalf S, Nigel C, Maria S, Markus K, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines[J]. Eur Urol, 2011, 59(6) :1009-1018.
  • 7Laturnus M, Jocham D, Sommerauer M. Recurrent bladder cancer after BCG instillation therapy. Local therapy options.'? [J]. UrologeA, 2012, 51(9) :1209-1219.
  • 8Chen G, He YF, Wu XH, et al. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer [J]. Braz J Med Biol Res, 2012, 45(8) :771-776.
  • 9Lv YY, Ding GB, Zhai JH, et al. A superparamagnetic Fe304- loaded polymeric nanocarrier for targeted delivery of evodiamine with enhanced antitumor efficacy [ J]. Colloid Surface B, 2013, 110(1):411-418.
  • 10Tanmoy S, Timothy W, Jayanth P. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy[J].Biomaterials, 2013, 34(21):5163-5171.

二级参考文献54

共引文献43

同被引文献15

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部